Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyeong Jin | - |
dc.contributor.author | Song, Ji Eun | - |
dc.contributor.author | Kim, Ji Yoon | - |
dc.contributor.author | Bae, Jae Hyun | - |
dc.contributor.author | Kim, Nam Hoon | - |
dc.contributor.author | Yoo, Hye Jin | - |
dc.contributor.author | Kim, Hee Young | - |
dc.contributor.author | Seo, Ji A. | - |
dc.contributor.author | Kim, Nan Hee | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.contributor.author | Baik, Sei Hyun | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.date.accessioned | 2021-08-30T13:03:03Z | - |
dc.date.available | 2021-08-30T13:03:03Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2305-5839 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/52673 | - |
dc.description.abstract | Background: Radioactive iodine (RAI) treatment is a standard treatment in differentiated thyroid cancer (TC). However, its adverse effects on cardiovascular diseases (CVDs) have not been clearly elucidated. Methods: In this retrospective cohort study based on the Korean National Health Insurance Service-National Health Screening Cohort (2002-2015), we analyzed 4,845 patients with TC with a median followup of 66 months. We evaluated and compared the risk of CVD between patients treated with and without RAI therapy. The primary CVD outcome was defined as a composite of ischemic stroke (IS), ischemic heart disease (IHD), hemorrhagic stroke (HS), or heart failure (HF). Results: Overall, 2,533 patients (52.3%) received RAI treatment with a median cumulative dosage of 103 mCi [interquartile range (IQR), 40-162 mCi]. The incidence of the primary CVD outcome in patients who did not receive RAI therapy and those who did was 17.32 [95% confidence interval (CI), 15.07-19.90] and 13.96 (95% CI, 12.17-16.01) per 1,000 person-years, respectively, indicating an adjusted hazard ratio (HR) of 0.87 (95% CI, 0.71-1.07) after multivariate adjustments for variable confounding factors. The risks of IS (HR, 0.83; 95% CI, 0.51-1.34), IHD (HR, 0.90; 95% CI, 0.71-1.13), HS (HR 1.01; 95% CI, 0.49-2.09), and HF (HR 0.89; 95% CI, 0.49-1.63) were comparable between the patients who received RAI therapy and those who did not. There was no cumulative dose-dependent risk for CVD in TC patients who received RAI treatment. Conclusions: RAI treatment is a prevalent and crucial treatment for TC, and has been used in more than half of TC patients in Korea from 2004 to 2015. This study found no significant between-group difference for the CVD risk in patients with TC who received RAI treatment and those who did not, giving further evidence to allay concerns related to the adverse effects of RAI. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AME PUBL CO | - |
dc.subject | RADIOIODINE TREATMENT | - |
dc.subject | MORTALITY | - |
dc.subject | THERAPY | - |
dc.subject | RISK | - |
dc.subject | ASSOCIATION | - |
dc.subject | EPIDEMIC | - |
dc.title | Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.contributor.affiliatedAuthor | Seo, Ji A. | - |
dc.contributor.affiliatedAuthor | Kim, Nan Hee | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Mook | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.identifier.doi | 10.21037/atm-20-5222 | - |
dc.identifier.wosid | 000581630100029 | - |
dc.identifier.bibliographicCitation | ANNALS OF TRANSLATIONAL MEDICINE, v.8, no.19 | - |
dc.relation.isPartOf | ANNALS OF TRANSLATIONAL MEDICINE | - |
dc.citation.title | ANNALS OF TRANSLATIONAL MEDICINE | - |
dc.citation.volume | 8 | - |
dc.citation.number | 19 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | RADIOIODINE TREATMENT | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | EPIDEMIC | - |
dc.subject.keywordAuthor | Thyroid neoplasms | - |
dc.subject.keywordAuthor | radioactive iodine treatment (RAI treatment) | - |
dc.subject.keywordAuthor | cardiovascular disease (CVD) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.